Creating engineered blood vessels that avoid immune rejection
Immunoevasive Engineered Living Blood Vessels
This study is working on creating new blood vessels that are made from specially modified cells, so they can better fit into your body without being rejected by your immune system, making them a promising option for people needing blood vessel replacements.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beth Israel Deaconess Medical Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11098751 on NIH RePORTER |
What this research studies
This research focuses on developing engineered living blood vessels using advanced genetic editing techniques to create cells that are less likely to be rejected by the immune system. By modifying human pluripotent stem cells to eliminate certain immune markers and enhance tolerogenic factors, the team aims to produce blood vessels that can integrate more effectively into the body. The engineered vessels will be designed to mimic the natural structure of blood vessels, ensuring they function properly when implanted. The project will also explore various strategies to improve the immune compatibility of these vessels.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who need vascular interventions, such as those with aneurysms or other arterial conditions.
Not a fit: Patients with conditions unrelated to vascular health or those who are not candidates for vascular surgery may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective treatments for patients requiring vascular grafts or replacements.
How similar studies have performed: Previous research has shown promise in using engineered tissues for transplantation, suggesting that this approach could be viable.
Where this research is happening
Boston, United States
- Beth Israel Deaconess Medical Center — Boston, United States (Active)
Researchers
- Principal investigator: Chaikof, Elliot — Beth Israel Deaconess Medical Center
- Study coordinator: Chaikof, Elliot
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.